STAT

Opinion: We need better regulation of stem cell therapies, especially rogue clinics

Many stem cell clinics mimic legitimate protocols. But the payment is in the clinic's bank and the patient is long gone before it becomes clear that its unproven therapy was…

Rogue stem cell clinics continue to victimize hopeful patients seeking cures for cancer, Parkinson’s disease, autism, chronic pain, and more.

Most of these treatments are unproven and unsupported by evidence, wasting precious time and health care dollars for desperate patients and often doing more harm than good to patients’ health and survival.

Yet public demand for stem cell treatments is outpacing our ability to regulate them. Government agencies like the Food and Drug Administration and the Federal Trade Commission should be stepping up to the plate to do this, but it isn’t likely that the money will be found soon to do that. It’s going to take a larger effort that includes legislators and medical associations who are already empowered to move against these clinics.

We are at a tipping point in medicine when it comes to using our own

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks